Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

GKOS

Glaukos (GKOS)

Glaukos Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:GKOS
DateHeureSourceTitreSymboleSociété
20/05/202413h00Edgar (US Regulatory)Form 8-K - Current reportNYSE:GKOSGlaukos Corporation
17/05/202401h45Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:GKOSGlaukos Corporation
15/05/202421h37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:GKOSGlaukos Corporation
01/05/202422h05Business WireGlaukos Announces First Quarter 2024 Financial ResultsNYSE:GKOSGlaukos Corporation
16/04/202422h05Business WireGlaukos Announces the Release of its 2023 Sustainability ReportNYSE:GKOSGlaukos Corporation
10/04/202413h00Business WireGlaukos to Release First Quarter 2024 Financial Results after Market Close on May 1NYSE:GKOSGlaukos Corporation
03/04/202413h00Business WireGlaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)NYSE:GKOSGlaukos Corporation
01/04/202413h00Business WireGlaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual MeetingNYSE:GKOSGlaukos Corporation
05/03/202402h07Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NYSE:GKOSGlaukos Corporation
23/02/202423h23Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NYSE:GKOSGlaukos Corporation
21/02/202422h05Business WireGlaukos Announces Fourth Quarter and Full Year 2023 Financial ResultsNYSE:GKOSGlaukos Corporation
13/02/202423h41Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NYSE:GKOSGlaukos Corporation
31/01/202413h00Business WireGlaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21NYSE:GKOSGlaukos Corporation
09/01/202413h00Business WireGlaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue GuidanceNYSE:GKOSGlaukos Corporation
20/12/202313h00Business WireGlaukos Announces Participation in the J.P. Morgan Healthcare ConferenceNYSE:GKOSGlaukos Corporation
14/12/202314h04Dow Jones NewsFDA Approves Glaukos' New Drug Application for iDose TRNYSE:GKOSGlaukos Corporation
14/12/202313h00Business WireGlaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)NYSE:GKOSGlaukos Corporation
07/11/202313h00Business WireGlaukos Announces Participation in Stifel Healthcare ConferenceNYSE:GKOSGlaukos Corporation
01/11/202321h38Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:GKOSGlaukos Corporation
01/11/202321h05Business WireGlaukos Announces Third Quarter 2023 Financial ResultsNYSE:GKOSGlaukos Corporation
31/10/202312h00Business WireGlaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual MeetingNYSE:GKOSGlaukos Corporation
11/10/202313h00Business WireGlaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023NYSE:GKOSGlaukos Corporation
23/08/202313h00Business WireGlaukos Announces Participation in Wells Fargo Healthcare ConferenceNYSE:GKOSGlaukos Corporation
02/08/202322h05Business WireGlaukos Announces Second Quarter 2023 Financial ResultsNYSE:GKOSGlaukos Corporation
17/07/202313h00Business WireGlaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.NYSE:GKOSGlaukos Corporation
12/07/202313h00Business WireGlaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023NYSE:GKOSGlaukos Corporation
28/06/202322h21Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NYSE:GKOSGlaukos Corporation
12/06/202323h54Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:GKOSGlaukos Corporation
07/06/202313h01Edgar (US Regulatory)Current Report Filing (8-k)NYSE:GKOSGlaukos Corporation
05/06/202313h00Business WireGlaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)NYSE:GKOSGlaukos Corporation
 Showing the most relevant articles for your search:NYSE:GKOS

Dernières Valeurs Consultées

Delayed Upgrade Clock